Cargando…

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

BACKGROUND: The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. METHODS: Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macdougall, Iain C., Bock, Andreas H., Carrera, Fernando, Eckardt, Kai-Uwe, Gaillard, Carlo, Van Wyck, David, Roubert, Bernard, Nolen, Jacqueline G., Roger, Simon D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	CLINICAL SCIENCE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209879/ https://www.ncbi.nlm.nih.gov/pubmed/24891437 http://dx.doi.org/10.1093/ndt/gfu201

Ejemplares similares

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017)

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
por: Macdougall, Iain C., et al.
Publicado: (2017)

The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
por: Macdougall, Iain C., et al.
Publicado: (2014)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review
por: Aksan, Aysegül, et al.
Publicado: (2022)

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial
por: Gaillard, Carlo A., et al.
Publicado: (2016)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia
por: Basha, Ahmad, et al.
Publicado: (2021)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
por: Macdougall, Iain C., et al.
Publicado: (2017)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial
por: Trenkwalder, Claudia, et al.
Publicado: (2017)

Ferric Carboxymaltose in the Treatment of Iron-Deficiency Anaemia in Paediatric Patients with Anastomotic Ulcers
por: Udina, Chiara, et al.
Publicado: (2022)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2013)

Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study
por: Dottori, Ludovica, et al.
Publicado: (2023)

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients
por: Qunibi, Wajeh Y., et al.
Publicado: (2011)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia
por: Huguet, Jose María, et al.
Publicado: (2022)

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
por: Theidel, Ulrike, et al.
Publicado: (2017)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
por: Hofman, Jesse M. G., et al.
Publicado: (2018)

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency
por: Calvet, Xavier, et al.
Publicado: (2012)

Treatment of Iron Deficiency With Intravenous Ferric Carboxymaltose in General Practice: A Retrospective Database Study
por: Kuster, Martina, et al.
Publicado: (2015)

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
por: Bourguignon, Sandrine, et al.
Publicado: (2019)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
por: Adkinson, N Franklin, et al.
Publicado: (2017)

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding
por: Hagras, Ahmed M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dqrl1056pef3ap50q4l0loj32m